Author Correction: Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction

Affiliations

¹ Department of Medicine, Duke University, Durham, NC, USA. kuo.du@duke.edu.
² Department of Medicine, Duke University, Durham, NC, USA.
³ Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA.
⁴ Department of Neurology, Duke University, Durham, NC, USA.
⁵ Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
⁶ Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.
⁷ Department of Medicine, Mayo Clinic, Rochester, MN, USA.
⁸ Department of Medicine, Duke University, Durham, NC, USA. annamae.diehl@duke.edu.

Published Erratum

Kuo Du et al. Nat Commun. 2025.

. 2025 May 6;16(1):4195.

doi: 10.1038/s41467-025-59084-8.

¹ Department of Medicine, Duke University, Durham, NC, USA. kuo.du@duke.edu.
² Department of Medicine, Duke University, Durham, NC, USA.
³ Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA.
⁴ Department of Neurology, Duke University, Durham, NC, USA.
⁵ Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
⁶ Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.
⁷ Department of Medicine, Mayo Clinic, Rochester, MN, USA.
⁸ Department of Medicine, Duke University, Durham, NC, USA. annamae.diehl@duke.edu.

No abstract available

Erratum for

Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction.
Du K, Umbaugh DS, Wang L, Jun JH, Dutta RK, Oh SH, Ren N, Zhang Q, Ko DC, Ferreira A, Hill J, Gao G, Pullen SS, Jain V, Gregory S, Abdelmalek MF, Diehl AM. Du K, et al. Nat Commun. 2025 Mar 28;16(1):3038. doi: 10.1038/s41467-025-57616-w. Nat Commun. 2025. PMID: 40155379 Free PMC article.